Nucleai
Cancer detection
Nucleai has raised €9.9M across 2 funding rounds from 5 investors, most recently a Series A round in Jul 2020. Based in Tel Aviv, Israel; active in AI and Healthtech. Data as of 4 Nov 2026.
Tel Aviv, Israelwww.nuclaimd.com ↗
Total raised
€9.9M
€9,926,406
Funding rounds
2
Investors
5
distinct backers
Active since
2018-01
latest 2020-07
Funding by year
EUR raised per yearNucleai — funding by year — interactive chart.
Data table
| Nucleai — funding by year | |
|---|---|
| 2017 | €4.2M |
| 2020 | €5.8M |
Signals
High confidenceRaise-next likelihood9
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood8
base rate 11% (2+ rounds)
- ▲ 9y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-07-08 | Series A | €5.8M | Debiopharm Innovation Fund | View deal → |
| 2018-01-01 | Other | €4.2M | Brian Cooper,Grove Ventures,Nir Kalkstein,Vertex Ventures Israel | View deal → |